Hudson Bay Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Hudson Bay Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$898K	Buy	+50,000	New	+$773K	﹤0.01%	944
2025 Q2	–	Sell	-10,340	Closed	-$36.6K	–	1363
2025 Q1	$36.6K	Buy	+10,340	New	+$36.8K	﹤0.01%	1205
2024 Q3	–	Sell	-250,000	Closed	-$475K	–	847
2024 Q2	$475K	Sell	250,000 -248,000	-50%	-$481K	﹤0.01%	643
2024 Q1	$1.41M	Buy	498,000 +37,400	+8%	+$489K	0.01%	506
2023 Q4	$6.78M	Sell	460,600 -221,623	-32%	-$3.4M	0.04%	261
2023 Q3	$12.5M	Buy	682,223 +391,323	+135%	+$8.27M	0.1%	135
2023 Q2	$6.27M	Buy	+290,900	New	+$7.86M	0.05%	269

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Hudson Bay Capital Management's AMLX Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 50,000 shares worth $898K. The stake represents ﹤0.01% of the portfolio and ranks #944 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in AMLX as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in AMLX in Q2 2023 and has held it in 7 quarters since. The position peaked at $12.5M in Q3 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Hudson Bay Capital Management held 50,000 shares of Amylyx Pharmaceuticals worth $898K as of Q2 2026.
Amylyx Pharmaceuticals was a new Hudson Bay Capital Management position in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #944 holding.
Hudson Bay Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Hudson Bay Capital Management's Amylyx Pharmaceuticals position peaked at $12.5M in Q3 2023.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.